中国药业2017，Vol.26Issue(19)：70-72,3.DOI:10.3969/j.issn.1006-4931.2017.19.020
二甲双胍治疗奥氮平所致首发精神分裂症女性患者体质量增加的疗效及安全性分析
Clinical Efficacy and Safety of Metformin for Treating Weight Gain Induced by Olanzapine in First-Episode Patients with Schizophrenia
摘要
Abstract
Objective To observe the intervention effect of metformin for treating weight gain induced by olanzapine in first-episode female patients with schizophrenia. Methods Totally 70 female inpatients with schizophrenia were randomly divided into the interventiongroup and the control group, 35 cases in each group. The intervention group was given metformin combined with olanzapine, while the control group was given olanzapine. The changes in body weight, body mass index ( BMI ) , fasting blood glucose ( FBG ) and treatment emergent symptom scale ( TESS ) scores were compared between the two groups at baseline and after 8 weeks, all assessments were performed with blind manipulation by psychiatric staffs. Results After 8 weeks of treatment, 64 cases ( 91. 43% ) were completed, and there was no difference in the rate of abscission between the two groups ( P > 0. 05 ) . There were significant difference in body weight [( -1.7±3.1)kg vs.(0.6±3.2)kg],BMI[( -0.6±2.1)kg/m2 vs.(1±2.6)kg/m2],FBG[( -0.1±0.1)mmol/L vs.(0.1± 0. 3)mmol/L] between intervention group and control group( P < 0. 05). The adverse events in the control group and the intervention group were weight gain ( 3 cases ) and vomiting ( 3 cases ) . Conclusion The intervention effect and safety of metformin for treating weight gain induced by olanzapine in first-episode female patients with schizophrenia were good.关键词
二甲双胍/精神分裂症/首发/奥氮平/体质量Key words
metformin/schizophrenia/first-episode/olanzapine/body weight分类
医药卫生引用本文复制引用
范征莉..二甲双胍治疗奥氮平所致首发精神分裂症女性患者体质量增加的疗效及安全性分析[J].中国药业,2017,26(19):70-72,3.
